COMBINATION THERAPY WITH TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1

摘要

PROBLEM TO BE SOLVED: To provide specific tumor-targeted IL-2 variant immunocytokines, and tumor-targeted IL-2 variant immunocytokines in combination with specific antibodies that bind to human PC-L1.;SOLUTION: The invention provides a tumor-targeted IL-2 variant immunocytokine of a specific sequence in combination with an antibody which binds to human PD-L1, for use in the combination treatment for treating cancer or tumor, for use in the combination treatment for preventing or treating metastasis, for use in the combination treatment for treating inflammatory diseases, for use in the combination treatment for treating or delaying progression of an immune related disease such as tumor immunity, or for use in the combination treatment for stimulating an immune response or function, such as T cell activity.;SELECTED DRAWING: None;COPYRIGHT: (C)2020,JPO&INPIT